The authors conducted a study to determine whether prognostic factors and the applicability of prognostic systems vary by primary tumor site in patients treated with radiosurgery for brain metastases.
The authors evaluated data obtained in patients who underwent radiosurgery with or without whole-brain radiotherapy (WBRT) from 1991 to 2005 for newly diagnosed brain metastases. Four groups were analyzed: 1) all primary sites combined, 2) breast, 3) lung, and 4) melanoma primary sites. Kaplan–Meier, log-rank, Cox proportional hazard uni- and multivariate analysis, and recursive partitioning analysis (RPA) were used to assess prognostic factors and 4 prognostic systems: Radiation Therapy Oncology Group (RTOG) RPA, Graded Prognostic Assessment (GPA), basic score for brain metastases (BSBM), and the newly proposed Golden grading system (GGS). The GGS divides patients into 4 prognostic groups by age ≥ 65 years, Karnofsky Performance Scale (KPS) score < 70, and known presence of extracranial metastases.
Data acquired in 479 newly diagnosed patients with 1664 lesions were analyzed. The median survival time from diagnosis of brain metastases was 12.1 months; the median follow-up was 25.4 months in 73 patients who were censored. Survival and prognostic factors were equivalent for 369 patients treated with radiosurgery compared with 110 patients treated with radiosurgery and WBRT, so these subsets were combined. Multivariate analysis of all primary sites combined demonstrated age < 65 years, KPS score ≥ 70, no known extracranial metastases, and ≤ 3 brain metastases were associated with longer survival, and primary tumor control was not. In subgroup multivariate analysis of patients with breast, lung, or melanoma primaries, favorable factors included only primary tumor control in 87 patients with breast primary; age < 65 years, no known extracranial metastases, and ≤ 3 brain metastases in 169 patients with lung primary; and KPS ≥ 70 years, primary tumor control, and ≤ 3 brain metastases in 137 patients with melanoma primary. The median survival for ≤ 3 versus > 3 metastases was 15.6 and 16.9 months, respectively, for breast, 16.5 and 11.3 months for lung, and 9.0 and 5.7 months for melanoma. Analysis of the 4 prognostic systems (RTOG RPA, BSBM, GPA, and GGS) showed that each prognostic system's clinical applicability varied depending on primary tumor site. The RPA confirmed that GGS and primary tumor site are significant variables for prognosis.
Favorable prognostic factors for patients with newly diagnosed brain metastases treated with radiosurgery vary by primary site. The 4 prognostic grading systems analyzed were applicable to different primary sites depending on which prognostic factors each individual system incorporated. Therefore, the authors recommend further development and use of primary-specific prognostic systems.
Abbreviations used in this paper: BSBM = basic score for brain metastases; GGS = Golden grading system; GK = Gamma Knife; GPA = Graded Prognostic Assessment; HR = hazard ratio; KPS = Karnofsky Performance Scale; HR = hazard ratio; RPA = recursive partitioning analysis; RTOG = Radiation Therapy Oncology Group; UCSF = University of California, San Francisco; WBRT = whole-brain radiotherapy.
Address correspondence to: Penny K. Sneed, M.D., Department of Radiation Oncology, 550 Parnassus Avenue, L-08 (0226), University of California, San Francisco, California. email:
AndrewsDWScottCBSperdutoPWFlandersAEGasparLESchellMC: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet363:1665–16722004
AoyamaHShiratoHTagoMNakagawaKToyodaTHatanoK: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA295:2483–24912006
BhatnagarAKKondziolkaDLunsfordLDFlickingerJC: Recursive partitioning analysis of prognostic factors for patients with four or more intracranial metastases treated with radiosurgery. Technol Cancer Res Treat6:153–1602007
ChidelMASuhJHReddyCAChaoSTLundbeckMFBarnettGH: Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys47:993–9992000
Diener-WestMDobbinsTWPhillipsTLNelsonDF: Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys16:669–6731989
GasparLScottCRotmanMAsbellSPhillipsTWassermanT: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys37:745–7511997
Gaudy-MarquesteCRegisJMMuraccioleXLauransRRichardMABonerandiJJ: Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys65:809–8162006
GerosaMNicolatoAForoniRTomazzoliLBricoloA: Analysis of long-term outcomes and prognostic factors in patients with non–small cell lung cancer brain metastases treated by gamma knife radiosurgery. J Neurosurg102:Suppl75–802005
HijalTRajakesariSPatelSMuanzaT: Estrogen receptor status is a significant predictor of overall and brain metastasis-free survival in patients with breast cancer and brain metastases treated with trastuzumab. Int J Radiat Oncol Biol Phys69:Suppl 1S218–S2192007
LagerwaardFJLevendagPCNowakPJEijkenboomWMHanssensPESchmitzPI: Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys43:795–8031999
Le ScodanRMassardCMouret-FourmeEGuinebretierreJMCohen-SolalCDe LalandeB: Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys69:839–8452007
LorenzoniJDevriendtDMassagerNDavidPRuizSVanderlindenB: Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys60:218–2242004
NelsonCFlickingerJCBhatnagarAKondziolkaDBrufskyARosenzweigM: 2017: HER2/neu status doesn't affect patient survival following stereotactic radiosurgery for brain metastases from breast cancer. Int J Radiat Oncol Biol Phys66:S2192006
PriestmanTJDunnJBradaMRamplingRBakerPG: Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol)8:308–3151996
RadesDPluemerAVeningaTHanssensPDunstJSchildSE: Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer110:2285–22922007
SanghaviSNMiranpuriSSChappellRBuattiJMSneedPKSuhJH: Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys51:426–4342001
SneedPKSuhJHGoetschSJSanghaviSNChappellRBuattiJM: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys53:519–5262002
SperdutoPWBerkeyBGasparLEMehtaMCurranW: A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys70:510–5142008. (epub 2007 Oct 10)